In October, idarucizumab (Praxbind, Boehringer Ingelheim), a reversal agent specific to dabigatran, was approved by the FDA, but there is still no specific agents for Factor Xa inhibitor reversal. Predictably, manufacturers are scrambling to develop antidotes. Specifically, a lack of a specific reversal agent is one persisting area of contention. The various benefits and limitations of each of these agents have been contested within the medical community. These agents include a direct thrombin inhibitor, dabigatran (Pradaxa, Boehringer Ingelheim), and several Factor Xa inhibitors: apixaban (Eliquis, Bristol-Myers Squibb), edoxaban (Savaysa, Daiichi Sankyo) and rivaroxaban (Xarelto, Janssen Pharmaceuticals).
If you continue to have this issue please contact to HealioĪfter more than 60 years of having only warfarin as an option for oral anticoagulation, several target-specific oral anticoagulants have entered the market.
0 kommentar(er)
